ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $102.1429.

ANIP has been the subject of a number of research analyst reports. Truist Financial increased their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 14,642 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the completion of the transaction, the senior vice president directly owned 158,584 shares of the company’s stock, valued at approximately $14,125,076.88. This trade represents a 8.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 28,001 shares of company stock worth $2,446,934 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ANIP. Global Alpha Capital Management Ltd. raised its stake in shares of ANI Pharmaceuticals by 17.2% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after buying an additional 126,500 shares during the last quarter. UBS Group AG boosted its stake in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals in the third quarter worth about $32,992,000. Rubric Capital Management LP grew its holdings in ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after acquiring an additional 85,745 shares during the period. Finally, Balyasny Asset Management L.P. raised its position in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $78.66 on Tuesday. The firm’s fifty day simple moving average is $83.88 and its two-hundred day simple moving average is $82.94. The firm has a market capitalization of $1.77 billion, a P/E ratio of 48.26 and a beta of 0.51. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals has a 12-month low of $52.74 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.